Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 MCLA-128-based combinations in metastatic breast cancer
2017-002821-39Phase 2Completed
- Sponsor
- Merus
- Start
- Sep 2017
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of zenocutuzumab in breast cancer (2 cohorts), sponsored by Merus. Primary endpoint: Clinical benefit rate at 24 weeks per investigator. Started Sep 2017; status: completed.
02
Drugs
zenocutuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-002821-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002821-39.